Anthem Biosciences Ltd.
ANTHEMHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
5 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 5 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20250818 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251112 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260209 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260522 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260727 | 2026-06-30 | yes |
ANTHEM
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 885.60 |
| 52-week range | 592.4 – 957.8 |
| Return 1M | 1.25% |
| Return 3M | 16.27% |
| Return 1Y | 7.9% |
| Return 3Y | not reported for this period |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 418.00 |
| Other income | 25.00 |
| Total income | 443.00 |
| Cost of materials consumed | 149.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -2.00 |
| Employee benefit expense | 79.00 |
| Finance costs | 1.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.71 | -0.03 |
| institutions foreign | 0.03 | 0.01 |
| institutions domestic | 0.13 | 0.02 |
| mutual funds | 0.11 | 0.01 |
| public | 0.29 | 0.03 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 5 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|
| Revenue from operations | 540.00 | 550.00 | 423.00 | 611.00 | 418.00 |
| Other income | 23.00 | 48.00 | 34.00 | 51.00 | 25.00 |
| Total income | 563.00 | 598.00 | 457.00 | 662.00 | 443.00 |
| Cost of materials consumed | 162.00 | 201.00 | 185.00 | 165.00 | 149.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 69.00 | 22.00 | -42.00 | 50.00 | -2.00 |
| Employee benefit expense | 72.00 | 68.00 | 70.00 | 72.00 | 79.00 |
| Finance costs | 2.00 | 3.00 | 0.00 | 2.00 | 1.00 |
| Depreciation and amortisation | 26.00 | 34.00 | 35.00 | 40.00 | 30.00 |
| Other expenses | 46.00 | 41.00 | 53.00 | 56.00 | 43.00 |
| Total expenses | 377.00 | 369.00 | 301.00 | 385.00 | 299.00 |
| Profit before exceptional items and tax | 186.00 | 230.00 | 156.00 | 277.00 | 145.00 |
| Exceptional items | 0.00 | 0.00 | -25.00 | 1.00 | 0.00 |
| Profit before tax | 186.00 | 230.00 | 130.00 | 278.00 | 145.00 |
| Current tax | 50.00 | 64.00 | 38.00 | 90.00 | 35.00 |
| Deferred tax | 0.00 | -8.00 | -0.00 | -2.00 | -10.00 |
| Tax expense | 50.00 | 56.00 | 38.00 | 88.00 | 25.00 |
| Profit for the period | 136.00 | 173.00 | 93.00 | 190.00 | 120.00 |
| Profit attributable to owners | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Other comprehensive income | 2.00 | -2.00 | -1.00 | -1.00 | 1.00 |
| Total comprehensive income | 137.00 | 172.00 | 92.00 | 189.00 | 121.00 |
| Earnings per share, basic | 2.43 | 3.09 | 1.65 | 0.00 | 2.13 |
| Earnings per share, diluted | 2.42 | 3.06 | 1.64 | 0.00 | 2.11 |
Annual results, as filed
| Line | 2026-03-31 |
|---|---|
| Revenue from operations | 2,124.00 |
| Other income | 156.00 |
| Total income | 2,280.00 |
| Cost of materials consumed | 714.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | 99.00 |
| Employee benefit expense | 283.00 |
| Finance costs | 7.00 |
| Depreciation and amortisation | 134.00 |
| Other expenses | 196.00 |
| Total expenses | 1,431.00 |
| Profit before exceptional items and tax | 849.00 |
| Exceptional items | -24.00 |
| Profit before tax | 824.00 |
| Current tax | 241.00 |
| Deferred tax | -9.00 |
| Tax expense | 232.00 |
| Profit for the period | 592.00 |
| Other comprehensive income | -2.00 |
| Total comprehensive income | 590.00 |
| Earnings per share, basic | 0.00 |
| Earnings per share, diluted | 0.00 |
Balance sheet, as filed
| Line | 2025-09-30 | 2026-03-31 |
|---|---|---|
| Total assets | 3,284.00 | 3,429.00 |
| Non-current assets | 1,100.00 | 1,626.00 |
| Current assets | 2,184.00 | 1,803.00 |
| Property, plant and equipment | 762.00 | 780.00 |
| Capital work-in-progress | 263.00 | 264.00 |
| Goodwill | 0.00 | 0.00 |
| Other intangible assets | 7.00 | 0.00 |
| Inventories | 186.00 | 125.00 |
| Trade receivables | 577.00 | 591.00 |
| Cash and cash equivalents | 504.00 | 273.00 |
| Total equity and liabilities | 3,284.00 | 3,429.00 |
| Equity | 2,753.00 | 3,043.00 |
| Equity share capital | 112.00 | 112.00 |
| Other equity | 2,640.00 | 2,930.00 |
| Total liabilities | 532.00 | 387.00 |
| Non-current liabilities | 68.00 | 61.00 |
| Current liabilities | 464.00 | 326.00 |
| Borrowings, non-current | 37.00 | 28.00 |
| Borrowings, current | 69.00 | 23.00 |
| Trade payables | 78.00 | 75.00 |
Cash flow, as filed
| Line | 2025-09-30 | 2026-03-31 |
|---|---|---|
| Net cash from operating activities | 403.00 | 844.00 |
| Net cash from investing activities | -169.00 | -702.00 |
| Net cash from financing activities | 21.00 | -40.00 |
| Purchase of property, plant and equipment | 94.00 | 211.00 |
| Net increase in cash | 255.00 | 103.00 |
| con:CFO.BEFORE_TAX | 515.00 | 1,121.00 |
| con:INTEREST_RECEIVED.OPERATING | -31.00 | -79.00 |
| con:INTEREST_PAID.OPERATING | -5.00 | -7.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | -4.00 | 0.00 |
| con:TAX_PAID.OPERATING | 90.00 | 204.00 |
| con:CF_OTHER.OPERATING | 8.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 111.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 2.00 |
| con:PPE_DISPOSALS | 0.00 | 4.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2025-07-21 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|
| Promoter and promoter group | 74.69 | 0.75 | 0.75 | 0.75 | 0.71 |
| Domestic institutions | 3.61 | 0.07 | 0.08 | 0.12 | 0.13 |
| Mutual funds | 2.21 | 0.07 | 0.07 | 0.10 | 0.11 |
| Insurance companies | 0.38 | 0.00 | 0.00 | 0.01 | 0.02 |
| Foreign institutions | 1.50 | 0.02 | 0.01 | 0.01 | 0.03 |
| Government | — | 0.00 | 0.00 | — | — |
| Public | 25.31 | 0.25 | 0.25 | 0.25 | 0.29 |
| Non-institutional | 20.20 | 0.16 | 0.16 | 0.12 | 0.13 |
| Shares outstanding | 561610051 | 561610051 | 561610051 | 561713851 | 563384760 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-27 | Q1FY27 | CHIEF EXECUTIVE OFFICER, RELATIONS) | Read the call |
| 2026-05-22 | Q4FY26 | CHIEF EXECUTIVE OFFICER, SECURITIES | Read the call |
| 2026-02-09 | Q3FY26 | CHIEF EXECUTIVE OFFICER, SECURITIES LIMITED | Read the call |
| 2025-11-12 | Q2FY26 | Read the call | |
| 2025-08-18 | Q1FY26 | Ankush Mahajan:, Vivek Agrawal: | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY26 | Q1FY27 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|---|
| Capex | So I just wanted to ask, what is the expected amount of capex in unit 3 and unit 4 in the coming years in number wise, I mean? | Sir, lastly on your Unit 4, can you provide some like current status where we have reached, how much capex we have already incurred in Unit 4 and what… | With the new block coming on stream in Unit-II, and we have commissioned in Q1 as well, can you talk about the revenue potential from these two capaci… | As we are starting work or doing work on Unit-4, you mentioned that, there's a fair bit of order that you're sort of building up, but how should we th… | On the point, which you had asked on capacity, I don't see with the capacity additions that we have made in the last financial year with respect to Un… |
| Capital allocation | Well, the cost of acquisition is so onerous that it may not be even commercially viable. | Largely they leave the team untouched for a year or 2 because it's a new acquisition for them. | — | — | Unfortunately, we haven't come across the right candidate, and I've said this ad nauseam and I'll repeat it again, we will not do an acquisition for t… |
| Costs | — | So, we have a fair degree of visibility there, because these need to be manufactured and there's a lot of raw material that need to be procured. | So, whatever we had procured from the outsourced vendor, that inventory has reduced and now it has been converted into raw materials because we are do… | If we are dependent on some for critical raw materials or a critical input from sources outside of India or which are not under our control, we work q… | We source the raw material, manufacture the intermediates, manufacture the API and supply to the customer, and we are not reliant on any external sour… |
| Debt and cash | — | Lastly on any working capital changes that has happened over last let's say quarter or two? | — | — | — |
| Demand | And we got a nice bump in terms of sales in the last quarter because of the increased demand from these customers. | We have very high degree of visibility because 60% of what we need to do, we already have order book. | But at the same time, if we are over demand for our facilities, for our CDMO business or CMO business in that case, we would actually tend to divert r… | Our underlying demand remains robust and our historically strongest quarter, which is the 4th Quarter, is still ahead and we are confident of deliveri… | I wanted to understand what steps are we taking to build a pipeline in large molecule, and wanted to delve deeper into the BD side of large molecule, … |
| Guidance | — | We expect all these units to be completely full and that's the reason why Unit 4 is what we are setting up. | We expect that on a full-stream basis, if it comes up, the long-term target on this is also to deliver about 1.4x - 1.5x on asset turnover. | Just to want to understand your full year guidance. | I think mostly it's behind us, and we expect that this will have a very positive impact on Anthem's top line and bottom line. |
| Margin | The EBITDA was INR214.3 crores with the margins, EBITDA margins at 38%. | What gives us the thing that we'll sustain the margin this year, as I as we said earlier, our order book is 60% already in the bag. | Anthem Biosciences Limited November 10, 2025 Other expenses have broadly been in the same zip code when it comes to H1 FY26 and H1 FY25. That's someth… | 671 crore, which gave us an EBITDA margin of 41.5%. | 990 crores, which included other income, with EBITDA margins of 43.4%. |
| People | What is the capacity utilization in custom synthesis in the last quarter and fermentation segment? | Can you update on the capacity utilization at Unit 1, 2 and Neo Anthem as of first quarter and how should we think about utilization levels in these u… | Also, if you can help us with Unit-III utilization, suspecting it might not be fully utilized yet. | I have one question on the capacity utilization. | — |
| Pricing | This is regarding generally the pricing environment, given the recent developments around MFN policy, the political rhetoric around drug pricing. | — | — | I know you mentioned in the past Anthem Biosciences Limited February 05, 2026 that you are also going to be competitive in terms of pricing, but how d… | — |
| Revenue growth | — | Secondly, in the past when you've guided for growth both on top line and PAT, it appears that clearly, we are expecting our margin to maintain at thes… | So, if the employee addition will be in a calibrated manner, and you will have a revenue growth next 2-3 years, would the current level of margins be … | What we had mentioned was, we would look at a revenue growth estimate of about 20% with EBITDA margins remaining constant, margin profile remaining st… | 2,280 crores, which was a growth of 18% over last year. |